HIV Protease Inhibitors, Ritonavir and Saquinavir are Potent Inhibitors of Calcium Activated Neutral Peptidases, Calpains
Posted Jun 09 2010 5:00pm
Description of Invention: This invention discloses a novel use for compounds that are inhibitors of the HIV Protease: specifically, the invention shows that HIV protease inhibitors are also potent inhibitors of Calcium Activated Neutral Proteases (Calpain). Activation of calpain plays a central role in tissue destructive processes following tissue trauma caused by, for example, stroke, heart attack, brain trauma, and spinal cord injury. Thus specific inhibition of calpain is an important therapeutic target in these disease processes. The estimated total market for these classes of therapeutic agents is on the order $500 million to 1 billion annually. The inventor has specifically demonstrated that in vitro the HIV protease inhibitors ritonavir and saquinavir are also potent inhibitors of calpain. This technology has a variety of practical applications: 1) Existing HIV proteases may be used as calpain inhibitors; 2) Existing HIV protease inhibitors which are FDA approved drugs will require less studies to develop as therapeutics; 3) HIV proteases inhibitors are small molecules with oral availability; 4) Other lead compounds developed as HIV protease inhibitors, but not commercialized, may be reevaluated as calpain inhibitors; 5) HIV protease inhibitors used as calpain inhibitors will not require chronic administration; and 6) calpain inhibitors may address therapeutic areas where there are not current effective therapies.
Inventors: Paolo B Depetrillo (NIAAA) Wenshuai Wan (NIAAA)
Portfolios: Internal Medicine Internal Medicine - Therapeutics Central Nervous System Central Nervous System - Therapeutics In-vitro Data
For Additional Information Please Contact: Fatima Sayyid MHPM NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325
Room 21, Rockville, MD 20852 United States Email: Fatima.Sayyid@nih.hhs.gov Phone: 301-435-4521 Fax: 301-402-0220